多中心前瞻性真实世界研究评估无创检测MASLD、MASH及高危MASH
本研究为多中心前瞻性真实世界研究,纳入226名参与者的328例活检病例,同步进行肝活检、MRI-PDFF、FibroScan及生化评估。研究评估常用无创检测对MASLD、MASH及高危MASH的诊断效能与最佳界值。结果显示CAP适合脂肪变性初筛,MRI-PDFF可准确定量肝脂肪,FAST可用于MASH风险分层,LSM可有效识别高危MASH。
要点
- CAP≥248 dB/m筛脂肪变性敏感性94.7%,304 dB/m特异性91.3%。
- FAST≥0.29时MASH诊断AUC为0.85,敏感性70.0%、特异性83.3%。
- LSM≥8.95 kPa识别高危MASH的AUC为0.92,敏感性86.5%、特异性84.1%。
核心结论
- CAP可作为脂肪变性的便捷筛查手段,MRI-PDFF可定量肝脂肪并为MASH提供额外信息。
- FAST可作为MASH风险分层的初步工具,LSM可有效识别高危MASH。
- 研究结果支持采用分步式无创策略进行MASLD评估与随访。
研究设计与样本
- 多中心前瞻性真实世界研究,纳入226名参与者的328例病例。
- 所有病例均同期进行肝活检、MRI-PDFF、FibroScan及生化评估。
- 依据组织病理学将病例分为MASL、MASH及高危MASH。
- 诊断效能采用ROC曲线下面积(AUC)、敏感性及特异性评估。
主要发现
- CAP以248 dB/m为界值检测组织学脂肪变性的AUC为0.80,敏感性94.7%,特异性30.4%。
- CAP阈值提高至304 dB/m时,特异性升至91.3%,敏感性降至60.3%。
- 两步法CAP–ALT算法敏感性78.3%,特异性82.6%,AUC为0.80。
- MRI-PDFF定量脂肪变性AUC为0.92,界值7.78%,敏感性77.1%,特异性100%。
- MRI-PDFF与组织病理学的诊断不一致主要见于轻度脂肪变性。
关键数值与推荐
- CAP检测脂肪变性:界值248 dB/m,AUC 0.80,敏感性94.7%,特异性30.4%。
- CAP检测脂肪变性:界值304 dB/m,敏感性60.3%,特异性91.3%。
- MRI-PDFF定量脂肪变性:界值7.78%,AUC 0.92,敏感性77.1%,特异性100%。
- FAST识别MASH:界值0.29,AUC 0.85,敏感性70.0%,特异性83.3%。
- MRI-PDFF识别MASH:界值17.78%,AUC 0.82,敏感性56.2%,特异性92.6%。
临床怎么用
- CAP可作为MASLD脂肪变性的初步筛查工具,低界值用于提高敏感性,高界值用于提高特异性。
- 两步法CAP–ALT算法可在敏感性与特异性之间取得平衡,适用于临床初筛。
- MRI-PDFF用于脂肪定量时以7.78%为界值可高特异性确认脂肪变性。
- FAST评分可作为MASH风险分层的初步工具,结果异常时进一步评估。
- LSM≥8.95 kPa提示存在高危MASH,可用于识别需要积极干预的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background and Aims Accurate non-invasive identification of metabolic dysfunction-associated steatohepatitis (MASH) and at-risk MASH remains a major unmet need in MASLD. We evaluated the diagnostic performance and optimal cutoffs of commonly used non-invasive tests (NITs) in a real-world setting. Methods In this multicentre prospective study, 328 cases from 226 participants underwent contemporaneous liver biopsy, MRI-PDFF, FibroScan and biochemical assessment, and were classified into MASL, MASH and at-risk MASH based on histopathology. Diagnostic performance was evaluated using area under the receiver operating characteristic curve (AUC), sensitivity and specificity. Results CAP at 248 dB/m detected histological steatosis with AUC of 0.80 (sensitivity: 94.7%, specificity: 30.4%); raising the threshold to 304 dB/m increased specificity to 91.3% (sensitivity: 60.3%). The two-step CAP–ALT algorithm achieved a more balanced sensitivity and specificity (78.3% and 82.6%, respectively; AUC: 0.80). MRI-PDFF quantified steatosis accurately (AUC: 0.92; cutoff: 7.78%; sensitivity: 77.1%; specificity: 100%) and differentiated grades, with diagnostic discordance versus histopathology mainly in mild disease. FAST score (AUC: 0.85; cutoff: 0.29; sensitivity: 70.0%; specificity: 83.3%) and MRI-PDFF (AUC: 0.82; cutoff: 17.78%; sensitivity: 56.2%; specificity: 92.6%) identified MASH, while LSM (AUC: 0.92; cutoff: 8.95 kPa; sensitivity: 86.5%; specificity: 84.1%) detected at-risk MASH. Conclusions CAP provides an accessible approach for steatosis detection, whereas MRI-PDFF offers quantitative assessment of liver fat and may provide additional information relevant to MASH. FAST may serve as an initial tool for MASH risk stratification, while LSM provides effective identification of at-risk MASH. These findings support a targeted, stepwise non-invasive approach to MASLD assessment and follow-up.
引用
- Diabetes, Obesity and Metabolism:Assessment of Non‐Invasive Tests for MASLD, MASH and At‐Risk MASH in a Multicentre Prospective Real‐World Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。